TR201809663T4 - Sübstitüe azaspiro(4.5)dekan deriveleri. - Google Patents

Sübstitüe azaspiro(4.5)dekan deriveleri. Download PDF

Info

Publication number
TR201809663T4
TR201809663T4 TR2018/09663T TR201809663T TR201809663T4 TR 201809663 T4 TR201809663 T4 TR 201809663T4 TR 2018/09663 T TR2018/09663 T TR 2018/09663T TR 201809663 T TR201809663 T TR 201809663T TR 201809663 T4 TR201809663 T4 TR 201809663T4
Authority
TR
Turkey
Prior art keywords
azaspiro
decan
dimethylamino
thiophen
phenyl
Prior art date
Application number
TR2018/09663T
Other languages
English (en)
Turkish (tr)
Inventor
WEGERT Anita
Nolte Bert
Linz Klaus
Harlfinger Stephanie
Kögel Babette-Yvonne
Ratcliffe Paul
Theil Fritz
Gröger Olga
Braun Birgit
Original Assignee
Gruenenthal Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gruenenthal Gmbh filed Critical Gruenenthal Gmbh
Publication of TR201809663T4 publication Critical patent/TR201809663T4/tr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/54—Spiro-condensed
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/96—Spiro-condensed ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Anesthesiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
TR2018/09663T 2014-07-15 2015-07-14 Sübstitüe azaspiro(4.5)dekan deriveleri. TR201809663T4 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP14002438 2014-07-15

Publications (1)

Publication Number Publication Date
TR201809663T4 true TR201809663T4 (tr) 2018-07-23

Family

ID=51211483

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2018/09663T TR201809663T4 (tr) 2014-07-15 2015-07-14 Sübstitüe azaspiro(4.5)dekan deriveleri.

Country Status (22)

Country Link
US (1) US10202345B2 (pl)
EP (1) EP3169665B1 (pl)
JP (1) JP6490187B2 (pl)
CN (1) CN106536514A (pl)
AU (1) AU2015291468B2 (pl)
BR (1) BR112017000766A2 (pl)
CA (1) CA2955073A1 (pl)
CY (1) CY1120443T1 (pl)
DK (1) DK3169665T3 (pl)
EA (1) EA201790186A1 (pl)
ES (1) ES2680820T3 (pl)
HR (1) HRP20180940T1 (pl)
HU (1) HUE039604T2 (pl)
LT (1) LT3169665T (pl)
MX (1) MX2017000519A (pl)
PL (1) PL3169665T3 (pl)
PT (1) PT3169665T (pl)
RS (1) RS57388B1 (pl)
SI (1) SI3169665T1 (pl)
TR (1) TR201809663T4 (pl)
TW (1) TW201607923A (pl)
WO (1) WO2016008583A1 (pl)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112017000762A2 (pt) * 2014-07-15 2017-11-21 Gruenenthal Gmbh derivados de azaspiro(4.5)decano substituído.
WO2019152688A1 (en) * 2018-01-31 2019-08-08 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA827340B (en) * 1981-11-12 1983-10-26 Upjohn Co Analgesic 1-oxa-,aza-and thia-spirocyclic compounds
DE3928182A1 (de) 1989-08-25 1991-02-28 Goedecke Ag Verfahren zur herstellung von gabapentin
DE19608653A1 (de) 1996-03-06 1997-09-11 Thomae Gmbh Dr K Pyrimido[5,4-d]pyrimidine, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
WO1999023076A1 (en) 1997-11-04 1999-05-14 Pfizer Products Inc. Therapeutically active compounds based on indazole bioisostere replacement of catechol in pde4 inhibitors
PT1187832E (pt) * 1999-06-02 2003-03-31 Warner Lambert Co Amino heterociclos uteis como agentes farmaceuticos
HUP9902374A3 (en) 1999-07-15 2002-11-28 Sanofi Aventis Process for producing spiro[(4-cyclohexanone)-[3h]indol-2'[1'h]-on derivatives and intermediates
DE19962924A1 (de) 1999-12-24 2001-07-05 Bayer Ag Substituierte Oxazolidinone und ihre Verwendung
US6759554B2 (en) 2001-04-24 2004-07-06 Massachusetts Institute Of Technology Copper-catalyzed formation of carbon-heteroatom and carbon-carbon bonds
DE10210190A1 (de) * 2002-03-07 2003-09-25 Sanol Arznei Schwarz Gmbh Aza-Spiroverbindungen
NZ538307A (en) 2002-09-09 2008-04-30 Janssen Pharmaceutica Nv Hydroxy alkyl substituted 1,3,8-triazaspiro[4.5]decan-4-one derivatives useful for the treatment of ORL-1 receptor mediated disorders
DE10252665A1 (de) * 2002-11-11 2004-06-03 Grünenthal GmbH 4-Aminomethyl-1-aryl-cyclohexylamin-Derivate
DE10252667A1 (de) 2002-11-11 2004-05-27 Grünenthal GmbH Spirocyclische Cyclohexan-Derivate
DE10360793A1 (de) 2003-12-23 2005-07-28 Grünenthal GmbH Spirocyclische Cyclohexan-Derivate
DE10360792A1 (de) 2003-12-23 2005-07-28 Grünenthal GmbH Spirocyclische Cyclohexan-Derivate
DE102004023635A1 (de) 2004-05-10 2006-04-13 Grünenthal GmbH Heteroarylsubstituierte Cyclohexyl-1,4-diamin-Derivate
DE102004039382A1 (de) 2004-08-13 2006-02-23 Grünenthal GmbH Spirocyclische Cyclohexan-Derivate
CA2579847A1 (en) 2004-09-13 2006-03-23 Merck & Co., Inc. Bicyclic anilide spirolactam cgrp receptor antagonists
AU2005287057A1 (en) 2004-09-17 2006-03-30 Osi Pharmaceuticals, Inc. (spirocyclylamido) aminothiophene compounds as c-Kit proto- oncogene inhibitors
DE102005016460A1 (de) 2005-04-11 2006-10-19 Grünenthal GmbH Spriocyclische Cyclohexanderivate zur Behandlung von Substanzabhängigkeit
DE102005038141A1 (de) * 2005-08-12 2007-02-15 Grünenthal GmbH Substituierte 8-(3-Aminopropyl)-1-phenyl-1,3,8-triaza-spiro[4.5]decan-4-on-Derivate
TW200800999A (en) 2005-09-06 2008-01-01 Astrazeneca Ab Novel compounds
AR057579A1 (es) 2005-11-23 2007-12-05 Merck & Co Inc Compuestos espirociclicos como inhibidores de histona de acetilasa (hdac)
EP1981854B1 (en) 2005-12-14 2011-06-01 Bristol-Myers Squibb Company Arylpropionamide, arylacrylamide, arylpropynamide, or arylmethylurea analogs as factor xia inhibitors
DE102005061428A1 (de) 2005-12-22 2007-08-16 Grünenthal GmbH Substituierte Cyclohexylmethyl-Derivate
ATE471311T1 (de) 2006-04-25 2010-07-15 Lilly Co Eli Inhibitoren von11-beta- hydroxysteroiddehydrogenase 1
DE102006019597A1 (de) 2006-04-27 2007-10-31 Grünenthal GmbH Spirocyclische Cyclohexan-Derivate
DE102006033114A1 (de) 2006-07-18 2008-01-24 Grünenthal GmbH Spirocyclische Azaindol-Derivate
DE102006033109A1 (de) 2006-07-18 2008-01-31 Grünenthal GmbH Substituierte Heteroaryl-Derivate
CA2662835A1 (en) 2006-09-18 2008-03-27 Remy Lemoine Octahydropyrrolo [3, 4-c] pyrrole derivatives and their use as antiviral agents
ATE532786T1 (de) 2006-09-22 2011-11-15 Janssen Pharmaceutica Nv Spirobenzazepine als vasopressinantagonisten
DE102007009319A1 (de) 2007-02-22 2008-08-28 Grünenthal GmbH Spirocyclische Cyclohexan-Derivate
DE102007009235A1 (de) 2007-02-22 2008-09-18 Grünenthal GmbH Spirocyclische Cyclohexan-Derivate
EP2128154B1 (en) 2007-03-01 2015-04-08 Mitsubishi Tanabe Pharma Corporation Benzimidazole compound and pharmaceutical use thereof
GB0707934D0 (en) 2007-04-24 2007-05-30 Glaxo Group Ltd Chemical compounds
WO2009111056A1 (en) 2008-03-06 2009-09-11 Amgen Inc. Conformationally constrained carboxylic acid derivatives useful for treating metabolic disorders
JP5529843B2 (ja) 2008-03-27 2014-06-25 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 置換シクロヘキシルジアミン
ES2464102T3 (es) * 2008-03-27 2014-05-30 Grünenthal GmbH Derivados de 4-aminociclohexano sustituidos
CN102046591B (zh) 2008-03-27 2014-12-03 格吕伦塔尔有限公司 羟甲基环己胺
AU2009228647B2 (en) 2008-03-27 2013-07-04 Grunenthal Gmbh Substituted spirocyclic cyclohexane derivatives
ES2375543T3 (es) * 2008-03-27 2012-03-01 Grünenthal GmbH Derivados de espiro(5.5)undecano.
AU2009277095B2 (en) 2008-07-30 2012-09-06 Purdue Pharma L.P. Buprenorphine analogs
UA107943C2 (xx) 2009-11-16 2015-03-10 Lilly Co Eli Сполуки спіропіперидину як антагоністи рецептора orl-1
GB201111775D0 (en) 2011-07-08 2011-08-24 Univ Bath Compounds and uses thereof
MX356344B (es) * 2011-10-20 2018-05-23 Oryzon Genomics Sa Compuestos de (hetero)arilciclopropilamina como inhibidores de lsd1.

Also Published As

Publication number Publication date
SI3169665T1 (en) 2018-08-31
LT3169665T (lt) 2018-07-10
WO2016008583A1 (de) 2016-01-21
PT3169665T (pt) 2018-07-12
HRP20180940T1 (hr) 2018-07-27
AU2015291468B2 (en) 2019-01-24
HUE039604T2 (hu) 2019-01-28
BR112017000766A2 (pt) 2017-11-21
WO2016008583A8 (de) 2016-03-31
AU2015291468A1 (en) 2017-03-02
PL3169665T3 (pl) 2018-12-31
CA2955073A1 (en) 2016-01-21
EP3169665B1 (de) 2018-05-09
MX2017000519A (es) 2017-05-01
RS57388B1 (sr) 2018-09-28
TW201607923A (zh) 2016-03-01
CY1120443T1 (el) 2019-07-10
JP2017520599A (ja) 2017-07-27
EP3169665A1 (de) 2017-05-24
CN106536514A (zh) 2017-03-22
JP6490187B2 (ja) 2019-03-27
EA201790186A1 (ru) 2017-07-31
US20160016903A1 (en) 2016-01-21
ES2680820T3 (es) 2018-09-11
US10202345B2 (en) 2019-02-12
DK3169665T3 (en) 2018-06-25

Similar Documents

Publication Publication Date Title
US6174878B1 (en) Topical use of kappa opioid agonists to treat otic pain
EA036446B1 (ru) Соединения и композиции для подавления активности shp2
RU2007120454A (ru) Производные хинуклидина и их применение в качестве антагонистов мускариновых рецепторов м3
JP2015514135A (ja) 新規組成物および方法
MX2010012186A (es) Antagonistas del receptor nmda para el tratamiento de transtornos neuropsiquitricos.
WO2016105448A1 (en) Imidazoline receptor type 1 ligands for use as therapeutics
JP2013532709A (ja) オピオイド誘発性痛覚過敏におけるシグマリガンドの使用
US20250228838A1 (en) Methods of use of cyclic amide derivatives to treat sigma receptor mediated disorders
BR112017017349B1 (pt) Composto e seu uso, composição, processo para preparar um composto e processo para separar um composto
RU2009103300A (ru) Производные 2-бензоилимидазопиридинов, их получение и их применение в терапии
JP2016523276A (ja) 間質性膀胱炎／膀胱痛症候群（ｉｃ／ｂｐｓ）に関連する疼痛の予防および治療のためのシグマリガンドの使用
AU2025267506A1 (en) Methods of treatment using BCN057 and BCN512
US20110237602A1 (en) Method for treating schizophrenia and related diseases
TR201809663T4 (tr) Sübstitüe azaspiro(4.5)dekan deriveleri.
CN102099032B (zh) 治疗α肾上腺素能介导的病症的方法
UA102844C2 (ru) 2-АМИНО-3-СУЛЬФОНИЛТЕТРАГИДРОПИРАЗОЛО[1,5-a]-ПИРИДО-ПИРИМИДИНЫ - АНТАГОНИСТЫ СЕРОТОНИНОВЫХ 5-HT6 РЕЦЕПТОРОВ, СПОСОБ ИХ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ
JP2010514682A5 (pl)
CA2826154A1 (en) Peripherially acting .mu. opioid antagonists
CA3223005A1 (en) Naltrexone for improving the effectiveness of 5-ht receptor subtype 2a, 2b or 2c agonists
SA05260389B1 (ar) فينيل ببرازين تجمع بين الميل إلى مستقبلات دوبامين d2- ومواضع اعادة امتصاص السيروتونين
RU2667954C2 (ru) Фармацевтическая композиция для лечения функциональных психических расстройств
JP2010530900A (ja) 中枢神経系活性を有する置換ピロリジン化合物
JP2010514684A5 (pl)
JPWO2018159716A1 (ja) アルコール使用障害の治療薬
JP2015096495A5 (pl)